Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 4 1Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Gynecologic 1Genitourinary 1Classical hematology 1CNS 1Breast 1

Conditions

Neurotoxicity Syndromes 1Lymphoma 1

Interventions

Cyclophosphamide 21fludarabine 12Rituximab 10Vincristine 6Etoposide 6Prednisone 5Doxorubicin 5pembrolizumab 4Radiotherapy 4Methotrexate 4Magnetic Resonance Spectroscopy 4Immunotherapy, Adoptive 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Dexamethasone 4venetoclax 3ibrutinib 3Nivolumab 3Imiquimod 3Ifosfamide 3Exercise 3Biopsy 368Ga-pentixafor 3fludarabine phosphate 2daratumumab 2Transplantation 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2Roflumilast 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Simvastatin × Lymphoid × Clear all
NCT04514029 2026-01-08

Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

Masonic Cancer Center, University of Minnesota

Phase EARLY_PHASE1 Active not recruiting
37 enrolled
Lymphoid

Lymphoma, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡